Tarceva (erlotinib) Coupons, Discounts & Cost
Tarceva (erlotinib) is an effective drug that helps block signals that promote the growth of tumor cells. One way to save money on the Tarceva retail cost regardless of income and insurance status is to use Tarceva coupons or discount cards from RXCoupons. Use this Erlotinib coupon at this online pharmacy and receive up to 75% off the sale price.
What should I know about this drug?
Tarceva (erlotinib) is an effective drug that helps block signals that promote the growth of tumor cells. It is mainly used as maintenance therapy for patients with serious diseases such as lung cancer. Tarceva is also used to treat other types of cancer. It is often used to treat pancreatic cancer.
Tarceva is well tolerated by patients. It has almost no side effects.
Tarceva: indications for use
Tarceva is used as a first-line drug for patients with lung cancer, as well as for maintenance therapy. Tarceva can also be used in non-small cell lung cancer after standard chemotherapy drugs.
Tarceva is used as a first-line drug for treating metastatic pancreatic cancer (in combination with gemcitabine).
Tarceva: how should I use this drug?
The daily dose is 150 mg. It is recommended to take the drug at least 1 hour before meals or 2 hours after meals.
Patients with non-small cell lung cancer are recommended to use 150 mg. The therapy should be discontinued in case of signs of toxicity.
Patients with pancreatic cancer are usually recommended to use Tarceva in a daily dose of 100 mg (in combination with gemcitabine).
Patients with liver function impairment of moderate severity require special attention. The dose of erlotinib should be reduced in case of toxicity symptoms. Erlotinib is not recommended in patients with severe forms of liver failure.
Tarceva can be used with caution in patients with moderate renal failure.
Smoking patients should increase the dose of erlotinib up to 300 mg per day.
Tarceva: what are the possible side effects?
The following undesirable phenomena may appear:
Gastrointestinal tract: stomatitis, abdominal pain, anorexia, gastrointestinal bleeding (in some cases, primarily in patients who used non-narcotic analgesics and warfarin simultaneously), gastrointestinal perforation.
Hepatobiliary system: liver failure, hyperbilirubinemia.
CNS: neuropathy, headache, depressive conditions.
Respiratory system: shortness of breath, cough.
Urinary system: nephritis, kidney failure, proteinuria.
Skin and subcutaneous tissue: erythematous rash, itching, alopecia, dry skin, acne, skin cracks (including those associated with dry skin and rash), folliculitis, hyperpigmentation, hirsutism, exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis.
Other reactions: conjunctivitis, keratitis, ulceration of the cornea, uveitis, perforation of the cornea.
Tarceva therapy may also lead to fatigue, fever, severe infections and weight loss.
What should I know about Tarceva contraindications?
The drug is not used in case of increased sensitivity to erlotinib.
Tarceva tablets are not allowed in pediatrics.
Tarceva tablets are not used in patients with severe forms of kidney and liver failure.
Care should be taken when prescribing erlotinib to patients with impaired renal activity, peptic ulcer, as well as to smokers.
It is forbidden to use erlotinib during pregnancy and lactation.
Tarceva: interactions
Erlotinib should be used with caution with ketoconazole and ciprofloxacin (it is better to avoid such combinations). Patients should reduce the dose of erlotinib in case of signs of toxicity.
Rifampicin may reduce the concentration of erlotinib.
Tarceva tablets may reduce the bioavailability of midazolam.
Drugs that affect gastric acid secretion may reduce the bioavailability of erlotinib. It is recommended to avoid combinations of erlotinib and drugs that change gastric acid secretion.
Combination therapy of erlotinib with warfarin and other coumarin anticoagulants leads to an increased risk of bleeding.
What should I know about Tarceva overdose?
Excessive doses of erlotinib may lead to diarrhea, severe skin reactions and elevated liver enzyme activity. Loperamide is allowed in case of severe diarrhea. If symptomatic therapy does not have a sufficient effect, then you should reduce the dose of erlotinib. It is necessary to stop the therapy in case of severe diarrhea, vomiting and anorexia.
Tarceva therapy can be continued after the disappearance of signs of overdose (under the supervision of a doctor).